Wegovy Online Prescription for Weight Loss
Wegovy (semaglutide 2.4 mg) is the first GLP-1 receptor agonist specifically approved for chronic weight management in Canada. Clinically proven to help patients lose 15–20% of their body weight, Wegovy represents a breakthrough in the treatment of obesity. Through TelePlus Care, you can consult with a licensed physician online to determine if Wegovy is right for you and receive your prescription without leaving home.
Book Your Appointment Now
Wegovy (semaglutide 2.4 mg) is the first GLP-1 receptor agonist specifically approved by Health Canada for chronic weight management, producing 14.9% average body weight loss in the STEP-1 trial over 68 weeks. TelePlus Care connects Alberta adults with BMI 30+ (or 27+ with comorbidities) to licensed physicians via secure virtual consultations for assessment and prescribing.
- Health Canada-approved specifically for chronic weight management
- 14.9% average body weight loss in STEP-1 trial (versus 2.4% placebo)
- 20% reduction in major cardiovascular events (SELECT trial)
- 16-week dose escalation managed by licensed Alberta physicians
What Is Wegovy?
Wegovy is a prescription medication containing semaglutide at a dose of 2.4 mg, manufactured by Novo Nordisk. It is specifically approved by Health Canada for chronic weight management in adults with obesity (BMI of 30 or greater) or adults who are overweight (BMI of 27 or greater) with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or dyslipidemia. Unlike Ozempic, which contains the same active ingredient but is approved for Type 2 diabetes, Wegovy was developed and dosed specifically for weight loss. It is administered as a once-weekly subcutaneous injection using a pre-filled pen device.
How Does Wegovy Work?
Wegovy works by mimicking GLP-1, a naturally occurring hormone released by your intestines after eating. Semaglutide at the 2.4 mg dose provides powerful appetite suppression and metabolic benefits that support sustained weight loss over time.
- Central appetite regulation -- Semaglutide acts on GLP-1 receptors in the hypothalamus, the brain's appetite control centre, reducing hunger signals and increasing feelings of fullness.
- Reduced food cravings -- Patients on Wegovy report significant decreases in food cravings, including cravings for high-calorie, high-fat foods.
- Slowed gastric emptying -- Wegovy delays stomach emptying, meaning food stays in your stomach longer and you feel satisfied for extended periods after meals.
- Improved satiety signalling -- The medication enhances your body's natural satiety signals, making it easier to stop eating when you are comfortably full.
- Insulin regulation -- Semaglutide improves insulin sensitivity and helps regulate blood sugar levels, which can reduce the cycle of blood sugar crashes and subsequent overeating.
- Reduced caloric intake -- Through these combined mechanisms, patients on Wegovy naturally consume 20–35% fewer calories per day without feeling deprived.
Wegovy Weight Loss Results: What the Clinical Trials Show
The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program is one of the largest and most comprehensive weight loss medication trial programs ever conducted. The results established semaglutide 2.4 mg as a landmark treatment for obesity.
- STEP 1 -- Adults with obesity but without diabetes lost an average of 14.9% of their body weight (approximately 33.7 pounds) over 68 weeks on Wegovy compared to 2.4% with placebo.
- STEP 2 -- Adults with Type 2 diabetes and obesity lost an average of 9.6% of their body weight over 68 weeks.
- STEP 3 -- When combined with intensive behavioural therapy, participants lost an average of 16% of their body weight over 68 weeks.
- STEP 4 -- Patients who continued Wegovy maintained their weight loss, while those switched to placebo regained approximately two-thirds of the weight they had lost.
- SELECT trial -- Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in overweight or obese adults with established cardiovascular disease.
- One-third of participants achieved 20% or greater weight loss -- A level of weight reduction previously achievable only through bariatric surgery.
Wegovy Dosage Schedule
Wegovy uses a carefully designed 16-week dose-escalation schedule to minimize gastrointestinal side effects and help your body gradually adjust to the medication. Each dose level is maintained for four weeks before increasing to the next level.
- Weeks 1–4: 0.25 mg once weekly -- The initiation dose. This dose is below the therapeutic threshold and is solely for tolerability. Most patients experience minimal or no side effects.
- Weeks 5–8: 0.5 mg once weekly -- The first dose increase. Some patients may begin to notice mild appetite changes at this level.
- Weeks 9–12: 1 mg once weekly -- Appetite suppression becomes more noticeable. Early weight loss may begin to appear on the scale.
- Weeks 13–16: 1.7 mg once weekly -- A transitional dose approaching the full therapeutic level. Weight loss typically accelerates.
- Week 17 and beyond: 2.4 mg once weekly -- The full maintenance dose. This is the dose used in clinical trials that produced 15–20% body weight reduction.
- Important: If you cannot tolerate a dose increase, your physician may extend the current dose period or reduce the dose temporarily. Never adjust your dosage without medical guidance.
Side Effects of Wegovy
The side effect profile of Wegovy is well-characterized from extensive clinical trials involving thousands of participants. Most side effects are gastrointestinal, predictable, and manageable. They are most common during dose escalation and typically diminish over time.
- Nausea -- Reported by approximately 44% of participants in clinical trials, though typically mild and transient. It is most common during the first weeks of each dose increase.
- Diarrhea -- Experienced by about 30% of patients, usually mild and self-limiting.
- Vomiting -- Reported by approximately 24% of patients, primarily during dose escalation phases.
- Constipation -- Occurs in about 24% of patients due to slowed gastric emptying.
- Abdominal pain -- Mild to moderate stomach discomfort affects approximately 20% of patients.
- Headache -- Reported by some patients, particularly during the initial weeks of treatment.
- Fatigue -- Temporary fatigue may occur as your body adjusts to reduced caloric intake.
- Injection site reactions -- Minor redness or irritation at the injection site is occasionally reported.
- Rare but serious: pancreatitis -- Severe abdominal pain radiating to the back requires immediate medical attention.
- Rare but serious: gallbladder disease -- Rapid weight loss can increase the risk of gallstones. Report any upper abdominal pain, nausea, or jaundice to your physician.
- Rare but serious: suicidal ideation -- Although rare, any changes in mood or thoughts of self-harm should be reported to your healthcare provider immediately.
Who Qualifies for Wegovy?
Wegovy is specifically approved for chronic weight management in adults who meet certain clinical criteria. During your TelePlus Care virtual consultation, your physician will conduct a thorough assessment to determine whether Wegovy is appropriate for you.
- BMI of 30 or greater (obesity) -- Adults classified as obese qualify for Wegovy regardless of the presence of comorbidities.
- BMI of 27 or greater with at least one comorbidity -- Overweight adults with conditions such as hypertension, Type 2 diabetes, dyslipidemia, or obstructive sleep apnea may qualify.
- Adults 18 years and older -- Wegovy is approved for use in adults. Pediatric use (ages 12+) may be considered in certain circumstances under specialist care.
- Previous weight loss attempts -- Candidates should have attempted weight loss through diet and exercise before starting pharmacotherapy.
- Commitment to lifestyle changes -- Wegovy is intended to be used alongside a reduced-calorie diet and increased physical activity for optimal results.
- No history of medullary thyroid cancer -- Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
- No history of pancreatitis -- Patients with a history of pancreatitis should discuss alternative treatments.
- Not pregnant or breastfeeding -- Wegovy should be discontinued at least two months before a planned pregnancy.
How to Get Wegovy Online at TelePlus Care
TelePlus Care makes accessing Wegovy straightforward through our secure virtual care platform. Our physicians specialize in obesity medicine and weight management, ensuring you receive expert guidance throughout your treatment journey.
- Step 1: Schedule your consultation -- Book a virtual appointment through our website. Choose a time that works for your schedule, with same-day availability often offered.
- Step 2: Share your health history -- Complete a detailed intake form covering your medical history, current medications, previous weight loss attempts, and health goals.
- Step 3: Virtual physician assessment -- Connect with a licensed physician via secure video or phone. Your physician will review your BMI, health history, and eligibility for Wegovy.
- Step 4: Prescription and pharmacy coordination -- If Wegovy is prescribed, you can fill your prescription at your preferred pharmacy. Your pharmacy team will help coordinate supply.
- Step 5: Injection training and support -- Your physician or pharmacist will provide guidance on self-administering the weekly injection, including proper injection technique and storage.
- Step 6: Ongoing follow-up -- Regular virtual check-ins allow your physician to monitor your weight loss, manage any side effects, and adjust your treatment plan as needed.
Cost of Wegovy in Canada
Wegovy is one of the newer weight management medications on the market, and its cost reflects its clinical efficacy and demand. Without insurance, Wegovy typically costs between $300 and $450 per month in Canada. Insurance coverage for Wegovy is expanding, particularly as Health Canada has specifically approved it for weight management. Many private insurance plans now cover Wegovy when prescribed according to approved criteria. Coverage depends on your specific plan and provider. Novo Nordisk offers patient support programs that may help eligible patients access Wegovy at reduced cost. Our TelePlus Care team can assist you in navigating insurance queries and connecting with patient assistance resources.
Wegovy vs Ozempic: Understanding the Difference
Wegovy and Ozempic both contain semaglutide and are manufactured by Novo Nordisk, but they serve different primary purposes and are dosed differently. Understanding these distinctions is important when considering your treatment options.
- Approved indication -- Wegovy is specifically approved for chronic weight management. Ozempic is approved for Type 2 diabetes management and is used off-label for weight loss.
- Maximum dose -- Wegovy reaches a maximum dose of 2.4 mg weekly, compared to Ozempic's maximum of 2 mg. The higher dose may contribute to greater weight loss.
- Dose escalation -- Wegovy has a 16-week escalation to reach the full dose with five dose steps. Ozempic has a shorter escalation with four dose steps.
- Clinical trial focus -- Wegovy's STEP trials specifically studied weight loss outcomes. Ozempic's SUSTAIN trials primarily studied diabetes outcomes with weight loss as a secondary endpoint.
- Insurance coverage -- Coverage for Wegovy (approved for weight loss) may differ from coverage for Ozempic (approved for diabetes). Some plans cover one but not the other.
- Availability -- Ozempic has been available longer and may be easier to obtain. Wegovy supply has faced intermittent shortages due to high demand.
- Same active ingredient -- Both contain semaglutide, so their mechanism of action and side effect profiles are essentially identical.
Your Fast and Convenient Healthcare Solution
Connect with a licensed healthcare provider from the comfort of your home. No referral needed — book your virtual appointment today.
Book Your Appointment Now
Serving Communities Across Alberta
Edmonton, Calgary, Red Deer, Lethbridge, Airdrie, Leduc, Fort McMurray, Sherwood Park, St. Albert, Grande Prairie, Medicine Hat, and surrounding areas across Alberta and Canada.
Teleplus care clinic is not an urgent care clinic. If you have an emergency please call 911 or go to the nearest urgent care facility.
